Article Per Year (5 Year)
p-Index From 2019 - 2024
1.204
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Raveinal
Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 8 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 8 Documents
Search

 1 
The Effectiveness of Antiplatelet Therapy in COVID-19 Patients: A Narrative Literature Review Muhammad Ridhwan Fatharanifurqan; Rudy Afriant; Raveinal; Fauzar; Drajad Priyono
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.751

Abstract

Coagulopathy is a feature of severe COVID-19 disease and contributes to an increased risk of thromboembolic complications and death. This literature review aimed to describe the effectiveness of antiplatelet therapy in COVID-19 patients. There is an inverse relationship between the likelihood of COVID-19 infection, duration of illness and death, and use of antiplatelets for primary prevention. A study showed that COVID-19 patients who did not receive antiplatelet drugs had three times the risk of dying with antiplatelet drugs. This study shows the strong effect of antiplatelet drugs on reducing the mortality rate of COVID-19 patients. Another study showed that COVID-19 patients who received antiplatelet drugs had 1.18 times the risk of dying than those without antiplatelet drugs. This study shows that antiplatelet therapy does not affect the reduction in mortality in patients hospitalized with COVID-19. In conclusion, the effectiveness of antiplatelet administration in COVID-19 patients is still unclear, so further research is needed.
The Effectiveness of Antiplatelet Therapy in COVID-19 Patients: A Narrative Literature Review Muhammad Ridhwan Fatharanifurqan; Rudy Afriant; Raveinal; Fauzar; Drajad Priyono
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.751

Abstract

Coagulopathy is a feature of severe COVID-19 disease and contributes to an increased risk of thromboembolic complications and death. This literature review aimed to describe the effectiveness of antiplatelet therapy in COVID-19 patients. There is an inverse relationship between the likelihood of COVID-19 infection, duration of illness and death, and use of antiplatelets for primary prevention. A study showed that COVID-19 patients who did not receive antiplatelet drugs had three times the risk of dying with antiplatelet drugs. This study shows the strong effect of antiplatelet drugs on reducing the mortality rate of COVID-19 patients. Another study showed that COVID-19 patients who received antiplatelet drugs had 1.18 times the risk of dying than those without antiplatelet drugs. This study shows that antiplatelet therapy does not affect the reduction in mortality in patients hospitalized with COVID-19. In conclusion, the effectiveness of antiplatelet administration in COVID-19 patients is still unclear, so further research is needed.
Allergy on HIV Infections: A Narrative Literature Review Muhammad Iqbal Andreas; Dwitya Elvira; Raveinal
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.771

Abstract

HIV infection causes not only immune insufficiency but also immune dysregulation. Following HIV infection, cytokine profiles change, with a production of IL-4 rising along with IL-5 and a decrease in INF-g. This literature review aimed to describe allergy on HIV infection. At the initial phase after infection, cytokines produced by Th1 and Th2 are balanced, but later as the infection progresses, cytokines produced by Th2 will rise, while cytokines produced by Th1 will fall. Elevation of IL-4 will make B cells produce more IgE. Patients with even lower CD4 still have this allergic phenomenon caused by IgE. Allergic manifestations of HIV include rhinitis, asthma, adverse cutaneous drug reactions (ACDR), immune reconstitution inflammatory syndrome, hyperallergic state (IRIS), and atopic dermatitis. In conclusion, it is important to consider allergic manifestations even in AIDS patients, especially incidents of ACDR and IRIS, which can be life-threatening.
The Role of Immunophenotyping in the Diagnosis of Acute Leukemia: A Narrative Literature Review Rivani Sintia Suratman; Rudy Afriant; Drajad Priyono; Raveinal; Fauzar
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.772

Abstract

Leukemia is the expansion of leukocyte cells in the bone marrow, which results in an increase in the number of leukocyte cells in the blood circulation and abnormal cell proliferation in the lymphatic tissue. The diagnosis of leukemia is established based on anamnesis, physical examination, and laboratory and confirmed by supporting examinations such as bone marrow aspiration to immunophenotyping. This literature review aimed to describe the role of immunophenotyping in the diagnosis of acute leukemia. The working process of immunophenotyping consists of a group of cells stained with a fluorochrome-conjugated antibody as a dye that is targeted to antigens on the cell surface. Most of these antigens are assigned a cluster of differentiation (CD) numbers. In conclusion, immunophenotyping analysis using multiparameter flow cytometry is an essential tool in detecting leukemia. Immunophenotyping examination is very useful for determining the diagnosis of leukemia. Targeted therapy is one of the modalities of leukemia therapy that is selective for certain cells that can be given based on the results of immunophenotyping.
Allergy on HIV Infections: A Narrative Literature Review Muhammad Iqbal Andreas; Dwitya Elvira; Raveinal
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.771

Abstract

HIV infection causes not only immune insufficiency but also immune dysregulation. Following HIV infection, cytokine profiles change, with a production of IL-4 rising along with IL-5 and a decrease in INF-g. This literature review aimed to describe allergy on HIV infection. At the initial phase after infection, cytokines produced by Th1 and Th2 are balanced, but later as the infection progresses, cytokines produced by Th2 will rise, while cytokines produced by Th1 will fall. Elevation of IL-4 will make B cells produce more IgE. Patients with even lower CD4 still have this allergic phenomenon caused by IgE. Allergic manifestations of HIV include rhinitis, asthma, adverse cutaneous drug reactions (ACDR), immune reconstitution inflammatory syndrome, hyperallergic state (IRIS), and atopic dermatitis. In conclusion, it is important to consider allergic manifestations even in AIDS patients, especially incidents of ACDR and IRIS, which can be life-threatening.
The Role of Immunophenotyping in the Diagnosis of Acute Leukemia: A Narrative Literature Review Rivani Sintia Suratman; Rudy Afriant; Drajad Priyono; Raveinal; Fauzar
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.772

Abstract

Leukemia is the expansion of leukocyte cells in the bone marrow, which results in an increase in the number of leukocyte cells in the blood circulation and abnormal cell proliferation in the lymphatic tissue. The diagnosis of leukemia is established based on anamnesis, physical examination, and laboratory and confirmed by supporting examinations such as bone marrow aspiration to immunophenotyping. This literature review aimed to describe the role of immunophenotyping in the diagnosis of acute leukemia. The working process of immunophenotyping consists of a group of cells stained with a fluorochrome-conjugated antibody as a dye that is targeted to antigens on the cell surface. Most of these antigens are assigned a cluster of differentiation (CD) numbers. In conclusion, immunophenotyping analysis using multiparameter flow cytometry is an essential tool in detecting leukemia. Immunophenotyping examination is very useful for determining the diagnosis of leukemia. Targeted therapy is one of the modalities of leukemia therapy that is selective for certain cells that can be given based on the results of immunophenotyping.
Target Therapy in Systemic Lupus Erythematosus: A Narrative Literature Review Muhamad Delfin; Raveinal; Dwitya Elvira
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 10 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i10.876

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the presence of autoantibodies against cells and involves many organ systems in the body. The Lupus Foundation of America estimates that around 1.5 million cases occur in America and at least 5 million cases occur worldwide. Every year it is estimated that there are around 16 thousand new cases of SLE. Various pro- and anti-inflammatory cytokines such as transforming growth factor (TGF), interleukin-10, B cell activating factor (BAFF), interferon-α, interleukin-17, and interleukin-23 play an important pathogenic role. Disruption of apoptotic cells and immune complexes is an important contributor to the development of this disease. Loss of immune tolerance increases antigenic load, excessive role of T cells, impaired B cell suppression and impaired transition of the immune response from T helper 1 (Th1) to Th2 which causes hyperactivity of B cells and produces pathogenic autoantibodies. The management of cases of severe or refractory SLE to conventional therapy has attracted a lot of attention in recent years, so that many researchers have developed several targeted therapies that have been tested on SLE, such as anti-CD 20 and CD 22 antibodies and BAFF inhibitors found in B lymphocyte cells. The Rituximab anti-CD 20 antibody target has been clinically proven to be able to improve the severity of SLE, while the effectiveness of other targeted therapies is still under research.
Target Therapy in Systemic Lupus Erythematosus: A Narrative Literature Review Muhamad Delfin; Raveinal; Dwitya Elvira
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 10 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i10.876

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the presence of autoantibodies against cells and involves many organ systems in the body. The Lupus Foundation of America estimates that around 1.5 million cases occur in America and at least 5 million cases occur worldwide. Every year it is estimated that there are around 16 thousand new cases of SLE. Various pro- and anti-inflammatory cytokines such as transforming growth factor (TGF), interleukin-10, B cell activating factor (BAFF), interferon-α, interleukin-17, and interleukin-23 play an important pathogenic role. Disruption of apoptotic cells and immune complexes is an important contributor to the development of this disease. Loss of immune tolerance increases antigenic load, excessive role of T cells, impaired B cell suppression and impaired transition of the immune response from T helper 1 (Th1) to Th2 which causes hyperactivity of B cells and produces pathogenic autoantibodies. The management of cases of severe or refractory SLE to conventional therapy has attracted a lot of attention in recent years, so that many researchers have developed several targeted therapies that have been tested on SLE, such as anti-CD 20 and CD 22 antibodies and BAFF inhibitors found in B lymphocyte cells. The Rituximab anti-CD 20 antibody target has been clinically proven to be able to improve the severity of SLE, while the effectiveness of other targeted therapies is still under research.
Co-Authors Drajad Priyono Drajad Priyono Dwitya Elvira Fauzar Muhamad Delfin Muhammad Iqbal Andreas Muhammad Ridhwan Fatharanifurqan Rivani Sintia Suratman Rudy Afriant